- Home
- COLL vs CIM Comparison
COLL vs CIM Comparison
Compare COLL & CIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- CIM
- Stock Information
- Founded
- COLL 2002
- CIM 2007
- Country
- COLL United States
- CIM United States
- Employees
- COLL N/A
- CIM N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- CIM Real Estate Investment Trusts
- Sector
- COLL Health Care
- CIM Real Estate
- Exchange
- COLL Nasdaq
- CIM Nasdaq
- Market Cap
- COLL 910.2M
- CIM 902.3M
- IPO Year
- COLL 2015
- CIM 2007
- Fundamental
- Price
- COLL $26.79
- CIM $11.92
- Analyst Decision
- COLL Strong Buy
- CIM Hold
- Analyst Count
- COLL 5
- CIM 2
- Target Price
- COLL $43.60
- CIM $16.00
- AVG Volume (30 Days)
- COLL 393.2K
- CIM 787.7K
- Earning Date
- COLL 05-08-2025
- CIM 05-08-2025
- Dividend Yield
- COLL N/A
- CIM 12.42%
- EPS Growth
- COLL 43.56
- CIM 61.77
- EPS
- COLL 1.86
- CIM 1.10
- Revenue
- COLL $631,449,000.00
- CIM $277,886,000.00
- Revenue This Year
- COLL $19.96
- CIM $9.17
- Revenue Next Year
- COLL $3.93
- CIM $1.73
- P/E Ratio
- COLL $14.31
- CIM $10.84
- Revenue Growth
- COLL 11.41
- CIM 22.95
- 52 Week Low
- COLL $23.23
- CIM $9.85
- 52 Week High
- COLL $42.29
- CIM $16.89
- Technical
- Relative Strength Index (RSI)
- COLL 43.80
- CIM 48.57
- Support Level
- COLL $25.87
- CIM $11.48
- Resistance Level
- COLL $27.95
- CIM $12.01
- Average True Range (ATR)
- COLL 1.50
- CIM 0.60
- MACD
- COLL 0.05
- CIM 0.15
- Stochastic Oscillator
- COLL 69.33
- CIM 95.83
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CIM Chimera Investment Corporation
Chimera Investment Corporation is a real estate investment trust engaged in investing in a portfolio of mortgage assets on a leveraged basis. These investments include a variety of government-sponsored agency residential mortgage-backed securities, or RMBS, non-agency RMBS, agency commercial mortgage-backed securities, residential mortgage loans, and other real estate-related securities. Agency mortgage-backed securities represent the share of this portfolio, while subprime residential mortgage loans and non-agency RMBS also make up substantial shares.